Apitegromab: Strengthened Regulatory Position and Dual-Site Strategy De-Risk Approval and Commercialization

H.C. Wainwright analyst Andres Y. Maldonado has maintained their bullish stance on SRRK stock, giving a Buy rating yesterday.

Andres Y. Maldonado has given his Buy rating due to a combination of factors, primarily the strengthened regulatory position of apitegromab following the resubmission of the BLA. He views the recent FDA interactions, including a productive meeting and site visit with no new corrective actions, as confirmation that the outstanding issues are now mainly centered on manufacturing logistics rather than clinical efficacy, which has already been supported by strong Phase 3 data.

Maldonado also highlights that adding a second U.S. fill‑finish site materially reduces operational and supply risk, giving the FDA two viable pathways to approval and ensuring commercial product availability ahead of the anticipated late‑2026 PDUFA date. In his assessment, this dual‑site strategy, combined with ongoing EMA review and visible progress on European launch preparation, significantly de‑risks both approval and early commercialization, supporting a favorable risk‑reward profile at current valuation levels.

In another report released yesterday, Raymond James also reiterated a Buy rating on the stock with a $60.00 price target.

Based on the recent corporate insider activity of 64 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SRRK in relation to earlier this year.